Structural and Preclinical Studies of Computationally Designed Non-Nucleoside Reverse Transcriptase Inhibitors for Treating HIV infection

Similar Items

• Structural and Pharmacological Evaluation of a Novel Non-nucleoside Reverse Transcriptase Inhibitor as a Promising Long Acting Nanoformulation for Treating HIV
  od: Kudalkar, Shalley N., i dr.
  Izdano: (2019)
• Covalent inhibitors for eradication of drug-resistant HIV-1 reverse transcriptase: From design to protein crystallography
  od: Chan, Albert H., i dr.
  Izdano: (2017)
• Structural insights into the recognition of nucleoside reverse transcriptase inhibitors by HIV‐1 reverse transcriptase: First crystal structures with reverse transcriptase and the active triphosphate forms of lamivudine and emtricitabine
  od: Bertoletti, Nicole, i dr.
  Izdano: (2019)
• From in silico hit to long-acting late-stage preclinical candidate to combat HIV-1 infection
  od: Kudalkar, Shalley N., i dr.
  Izdano: (2018)
• Discovery and crystallography of bicyclic arylaminoazines as potent inhibitors of HIV-1 reverse transcriptase
  od: Lee, Won-Gil, i dr.
  Izdano: (2015)